Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Advanced Research in Prostate Cancer 2.0
share announcement

Advanced Research in Prostate Cancer 2.0

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 4354

Special Issue Editor

Dr. Ruth Vinall

E-Mail Website
Guest Editor
Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, USA
Interests: prostate cancer; bladder cancer; natural products research; biomarkers; targeted therapy; miRNA; mechanisms of chemoresistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the past few years, we have witnessed major advances in prostate cancer treatments. The trend, as for many cancer types, is moving toward the development and clinical use of biomedicine-based approaches. For example, Sipuleucel-T, a prostate cancer vaccine which received FDA approval in 2010, is becoming more widely used in patients with metastatic disease. Pembrolizumab and Nivolumab, also immunotherapies, show much promise. Continued efforts in the area of natural products research indicate that natural bioactive products can help to reduce prostate cancer incidence and progression. Large-scale genomics projects have led to the ongoing development of several targeted therapies, and, importantly, the co-development of biomarkers will allow for the prediction and measurement of patient response. Lastly, implementation of innovative drug delivery technologies, for example, nanoparticles, is helping to improve drug response rates while minimizing off-target effects. This is certainly an exciting time for prostate cancer research. This Special Edition of Biomedicines entitled ‘Advanced Research in Prostate Cancer’ will include reviews that describe major advances which have occurred in the treatment of prostate cancer over the past few years as well as original research articles that describe preclinical and/or translational studies which will support future advances.

On behalf of the Biomedicines journal, it is my pleasure to invite you to submit an article to this Special Edition. Articles should be focused on the development and use, or potential use, of biomedicines, including natural bioactive molecules, biologics, vaccines, and/or targeted therapies to treat prostate cancer. Articles which outline how genetic analyses can guide the development and use of these treatment options, or which describe innovative drug delivery strategies, are also welcomed.

Dr. Ruth Vinall
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • immunotherapy
  • natural bioactive products
  • targeted therapies
  • vaccines
  • biologics

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 3502 KiB  
Article
Long-Term Treatment with Simvastatin Leads to Reduced Migration Capacity of Prostate Cancer Cells
by Mona Kafka, Rebecca Gruber, Hannes Neuwirt, Michael Ladurner and Iris E. Eder
Biomedicines 2023, 11(1), 29; https://doi.org/10.3390/biomedicines11010029 - 22 Dec 2022
Cited by 6 | Viewed by 1729
Abstract
Statins have been shown to improve survival of metastatic prostate cancer (mPCa). Nevertheless, their therapeutic use is still under debate. In the present study, we investigated the short-term effects of three different statins (simvastatin, atorvastatin and rosuvastatin) in various PCa cell lines mimicking [...] Read more.
Statins have been shown to improve survival of metastatic prostate cancer (mPCa). Nevertheless, their therapeutic use is still under debate. In the present study, we investigated the short-term effects of three different statins (simvastatin, atorvastatin and rosuvastatin) in various PCa cell lines mimicking androgen-sensitive and -insensitive PCa. Moreover, we generated three new PCa cell lines (LNCaPsim, ABLsim, PC-3sim) that were cultured with simvastatin over several months. Our data showed that the three statins expressed highly diverse short-term effects, with the strongest growth-inhibitory effect from simvastatin in PC-3 cells and almost no effect from rosuvastatin in any of the cell lines. Long-term treatment with simvastatin resulted in a loss of response to statins in all three cell lines, which was associated with an upregulation of cholesterol and fatty acid pathways as revealed through RNA sequencing. Despite that, long-term treated cells exhibited diminished spheroid growth and significantly reduced migration capacity per se and to differentiated osteoclasts. These findings were strengthened by reduced expression of genes annotated to cell adhesion and migration after long-term simvastatin treatment. Notably, mPCa patients taking statins were found to have lower numbers of circulating tumor cells in their blood with reduced levels of PSA and alkaline phosphatase. Our data suggest that long-term usage of simvastatin hampers the metastatic potential of PCa cells and may therefore be a potential therapeutic drug for mPCa. Full article
(This article belongs to the Special Issue Advanced Research in Prostate Cancer 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

29 pages, 1322 KiB  
Review
The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches
by Nur Erysha Sabrina Jefferi, Asma’ ‘Afifah Shamhari, Nur Khayrin Zulaikha Noor Azhar, Joyce Goh Yi Shin, Nur Annisa Mohd Kharir, Muhammad Afiq Azhar, Zariyantey Abd Hamid, Siti Balkis Budin and Izatus Shima Taib
Biomedicines 2023, 11(3), 826; https://doi.org/10.3390/biomedicines11030826 - 09 Mar 2023
Cited by 4 | Viewed by 2304
Abstract
Castration-resistant prostate cancer, or CRPC, is an aggressive stage of prostate cancer (PCa) in which PCa cells invade nearby or other parts of the body. When a patient with PCa goes through androgen deprivation therapy (ADT) and the cancer comes back or worsens, [...] Read more.
Castration-resistant prostate cancer, or CRPC, is an aggressive stage of prostate cancer (PCa) in which PCa cells invade nearby or other parts of the body. When a patient with PCa goes through androgen deprivation therapy (ADT) and the cancer comes back or worsens, this is called CRPC. Instead of androgen-dependent signalling, recent studies show the involvement of the estrogen pathway through the regulation of estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) in CRPC development. Reduced levels of testosterone due to ADT lead to low ERβ functionality in inhibiting the proliferation of PCa cells. Additionally, ERα, which possesses androgen independence, continues to promote the proliferation of PCa cells. The functions of ERα and ERβ in controlling PCa progression have been studied, but further research is needed to elucidate their roles in promoting CRPC. Finding new ways to treat the disease and stop it from becoming worse will require a clear understanding of the molecular processes that can lead to CRPC. The current review summarizes the underlying processes involving ERα and ERβ in developing CRPC, including castration-resistant mechanisms after ADT and available medication modification in mitigating CRPC progression, with the goal of directing future research and treatment. Full article
(This article belongs to the Special Issue Advanced Research in Prostate Cancer 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop